Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7343)
All Articles published online
|
Sep 21, 2011 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17(35): 3971-3975 [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i35/3971.htm |
| Number | Citing Articles |
| 1 |
Bruna Maria Roesler, Sandra Cecília Botelho Costa, José Murilo Robilotta Zeitune. Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer. ISRN Gastroenterology 2012; 2012: 1 doi: 10.5402/2012/935410
|
| 2 |
Hatun A. Alomar, Wafaa M. Elkady, Marwa M. Abdel-Aziz, Taghreed A. Ibrahim, Noha Fathallah. Anti-Heliobacter pylori and Anti-Inflammatory Potential of Salvia officinalis Metabolites: In Vitro and In Silico Studies. Metabolites 2023; 13(1): 136 doi: 10.3390/metabo13010136
|
| 3 |
Seng-Kee Chuah, Wei-Chen Tai, Chen-Hsiang Lee, Chih-Ming Liang, Tsung-Hui Hu. Quinolone-Containing Therapies in the Eradication ofHelicobacter pylori. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/151543
|
| 4 |
R Ozgur Karaca, Said Kalkisim, Akif Altinbas, Serta Kilincalp, Ilhami Yuksel, Mustafa T Goktas, Umit Yasar, Atilla Bozkurt, Melih O Babaoglu. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. Basic & Clinical Pharmacology & Toxicology 2017; 120(2): 199 doi: 10.1111/bcpt.12667
|
| 5 |
Natalie Vandeven, Paul Nghiem. Pathogen-Driven Cancers and Emerging Immune Therapeutic Strategies. Cancer Immunology Research 2014; 2(1): 9 doi: 10.1158/2326-6066.CIR-13-0179
|
| 6 |
Brygida Kwiatkowska, Maria Maślińska. Macrolide Therapy in Chronic Inflammatory Diseases. Mediators of Inflammation 2012; 2012: 1 doi: 10.1155/2012/636157
|
| 7 |
Chuan Wang, Zhifang Jia, Donghui Cao, Lili You, Meishan Jin, Xing Wu, Simin Wen, Xueyuan Cao, Jing Jiang, Valli De Re. Polymorphism of DNA Methyltransferase 3b and Association with Development and Prognosis in Gastric Cancer. PLOS ONE 2015; 10(8): e0134059 doi: 10.1371/journal.pone.0134059
|
| 8 |
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Sheila López-Góngora, Xavier Calvet. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterología y Hepatología (English Edition) 2018; 41(10): 654 doi: 10.1016/j.gastre.2018.11.021
|
| 9 |
Wenming Wu, Yunsheng Yang, Gang Sun. Recent Insights into Antibiotic Resistance inHelicobacter pyloriEradication. Gastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/723183
|
| 10 |
Hyun Chul Lim, Yong Jae Lee, Byoungrak An, Seung Woo Lee, Yong Chan Lee, Byung Soo Moon. Rifabutin‐based High‐dose Proton‐pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for Helicobacter pylori. Helicobacter 2014; 19(6): 455 doi: 10.1111/hel.12147
|
| 11 |
Tzung‐Shiun Wu, Huang‐Ming Hu, Fu‐Chen Kuo, Chao‐Hung Kuo. Eradication of Helicobacter pylori infection. The Kaohsiung Journal of Medical Sciences 2014; 30(4): 167 doi: 10.1016/j.kjms.2013.11.003
|
| 12 |
Angelo Zullo, Vincenzo De Francesco, Cesare Hassan, Lorenzo Ridola, Alessandro Repici, Vincenzo Bruzzese, Dino Vaira. Modified sequential therapy regimens for Helicobacter pylori eradication: A systematic review. Digestive and Liver Disease 2013; 45(1): 18 doi: 10.1016/j.dld.2012.08.025
|
| 13 |
Yanhua Wu, Donghui Cao, Limei Qu, Xueyuan Cao, Zhifang Jia, Tiancheng Zhao, Quan Wang, Jing Jiang. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget 2017; 8(38): 64066 doi: 10.18632/oncotarget.19318
|
| 14 |
Ping‐I Hsu, Wen‐Chi Chen, Feng‐Woei Tsay, Chih‐An Shih, Sung‐Shuo Kao, Huay‐Min Wang, Hsien‐Chung Yu, Kwok‐Hung Lai, Hui‐Hwa Tseng, Nan‐Jing Peng, Angela Chen, Chao‐Hung Kuo, Deng‐Chyang Wu. Ten‐Day Quadruple Therapy Comprising Proton‐Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin Achieves a High Eradication Rate for Helicobacter pylori Infection after Failure of Sequential Therapy. Helicobacter 2014; 19(1): 74 doi: 10.1111/hel.12085
|
| 15 |
Fariborz Mansour-Ghanaei, Zahra Pedarpour, Afshin Shafaghi, Farahnaz Joukar. Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication. Middle East Journal of Digestive Diseases 2017; 9(2): 100 doi: 10.15171/mejdd.2017.58
|
| 16 |
F. Sierra, J.D. Forero, M. Rey. Ideal treatment for Helicobacter pylori: A systematic review. Revista de Gastroenterología de México (English Edition) 2014; 79(1): 28 doi: 10.1016/j.rgmxen.2014.05.001
|
| 17 |
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Sheila López-Góngora, Xavier Calvet. Prevalencia de las resistencias de Helicobacter pylori tras el fracaso de una primera línea de tratamiento. Revisión sistemática. Gastroenterología y Hepatología 2018; 41(10): 654 doi: 10.1016/j.gastrohep.2018.06.014
|
| 18 |
Ben Wang, You‐Hua Wang, Zhi‐Fa Lv, Hui‐Fang Xiong, Hui Wang, Yang Yang, Yong Xie. Review: Efficacy and Safety of Hybrid Therapy for Helicobacter pylori Infection: A Systematic Review and Meta‐analysis. Helicobacter 2015; 20(2): 79 doi: 10.1111/hel.12180
|
| 19 |
Xuan Weng, Suresh Neethirajan, Adam Vogt. Single Cell Chemotactic Responses of Helicobacter pylori to Urea in a Microfluidic Chip. Applied Sciences 2016; 6(5): 139 doi: 10.3390/app6050139
|
| 20 |
Jhen-Hong Wong, Kuo-Hao Ho, Sean Nam, Wen-Li Hsu, Chia-Hsien Lin, Che-Mai Chang, Jaw-Yuan Wang, Wei-Chiao Chang. Store-operated Ca2+ Entry Facilitates the Lipopolysaccharide-induced Cyclooxygenase-2 Expression in Gastric Cancer Cells. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-12648-1
|
| 21 |
Seng‐Kee Chuah, Wei‐Chen Tai, Pin‐I Hsu, Deng‐Chyang Wu, Keng‐Liang Wu, Chung‐Mou Kuo, Yi‐Chun Chiu, Ming‐Luen Hu, Yeh‐Pin Chou, Yuan‐Hung Kuo, Chih‐Ming Liang, King‐Wah Chiu, Tsung‐Hui Hu. The Efficacy of Second‐Line Anti‐Helicobacter pylori Therapy Using an Extended 14‐Day Levofloxacin/Amoxicillin/Proton‐Pump Inhibitor Treatment – A Pilot Study. Helicobacter 2012; 17(5): 374 doi: 10.1111/j.1523-5378.2012.00960.x
|
| 22 |
Nuno Miguel de Almeida, Alexandra Fernandes, José Manuel Romãozinho, Paulo Freire, Maria M. Donato, Olga Cardoso, Cristina Luxo, Maria Augusta Cipriano, Carol Marinho, Carlos Calhau, Pedro Figueiredo. Correlation of NOD2 genotypes with Helicobacter pylori infection in a South‐European country. Advances in Digestive Medicine 2021; 8(3): 163 doi: 10.1002/aid2.13210
|
| 23 |
Natalie Amar, Avi Peretz, Yoram Gerchman. A cheap, simple high throughput method for screening native Helicobacter pylori urease inhibitors using a recombinant Escherichia coli , its validation and demonstration of Pistacia atlantica methanolic extract effectivity and specificity. Journal of Microbiological Methods 2017; 133: 40 doi: 10.1016/j.mimet.2016.11.022
|
| 24 |
Mu Feng, Hilda Namanja-Magliano, Saranathan Rajagopalan, Tanmay Mishra, Rodrigo G. Ducati, Brett M. Hirsch, Libusha Kelly, Wendy Szymczak, Jorge Eduardo Fajardo, Simone Sidoli, Andras Fiser, William R. Jacobs, Vern L. Schramm. MAT Gain of Activity Mutation in Helicobacter pylori Is Associated with Resistance to MTAN Transition State Analogues. ACS Infectious Diseases 2023; 9(4): 966 doi: 10.1021/acsinfecdis.2c00644
|
| 25 |
Mohammad Reza Esmaeili-Dooki, Hossein Shirdel, Mahmood Hajiahmadi. Eradication of Helicobacter pylori in Children by Triple Therapy Regimens of Amoxicillin, Omeprazole, and Clarithromycin or Azithromycin. Iranian Journal of Pediatrics 2015; 25(6) doi: 10.5812/ijp.2360
|
| 26 |
Hideo Tanaka. Epidemiologic Studies in Cancer Prevention and Screening. Statistics for Biology and Health 2013; 79: 65 doi: 10.1007/978-1-4614-5586-8_5
|
| 27 |
Halil Rakici, Remzi Adnan Akdoğan, Recep Bedir, Aysegul Copur, Arif Yilmaz. Comparison of standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. Journal of Digestive Diseases 2014; 15(9): 508 doi: 10.1111/1751-2980.12171
|
| 28 |
JING JIANG, DONG-HUI CAO, TETSUYA TSUKAMOTO, GUO-QING WANG, ZHI-FANG JIA, JIAN SUO, XUE-YUAN CAO. Anticancer effects of 4-vinyl-2,6-dimethoxyphenol (canolol) against SGC-7901 human gastric carcinoma cells. Oncology Letters 2013; 5(5): 1562 doi: 10.3892/ol.2013.1230
|
| 29 |
Wei-Chen Tai, Chien-Hua Chiu, Chih-Ming Liang, Kuo-Chin Chang, Chung-Mou Kuo, Yi-Chun Chiu, Keng-Liang Wu, Ming-Luen Hu, Yeh-Pin Chou, Shue-Shian Chiou, King-Wah Chiu, Chung-Huang Kuo, Tsung-Hui Hu, Ming-Tsung Lin, Seng-Kee Chuah. Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan. Gastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/932478
|
| 30 |
Reza Ghotaslou, Morteza Milani, Mohammad Taghi Akhi, Mohammad Saeid Hejazi, Mohammad Reza Nahaei, Alka Hasani, Yaeghob Sharifi. Relationship Between Drug Resistance and cagA Gene in Helicobacter pylori. Jundishapur Journal of Microbiology 2013; 6(10) doi: 10.5812/jjm.8480
|
| 31 |
Shu-Ping Xiao, Min Gu, Guo-Xin Zhang. Is levofloxacin-based triple therapy an alternative for first-line eradication ofHelicobacter pylori? A systematic review and meta-analysis. Scandinavian Journal of Gastroenterology 2014; 49(5): 528 doi: 10.3109/00365521.2014.887765
|
| 32 |
Deng-Chyang Wu, Chao-Hung Kuo, Feng-Woei Tsay, Wen-Hung Hsu, Angela Chen, Ping-I Hsu. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. Medicine 2016; 95(11): e2698 doi: 10.1097/MD.0000000000002698
|
| 33 |
Carlo‐Federico Zambon, Daniela Basso, Michela Pelloso, Alberto Tessari, Mario Plebani. Human Emerging and Re‐emerging Infections. 2015; : 607 doi: 10.1002/9781118644843.ch33
|
| 34 |
Stanisław Ferenc, Jan Gnus, Magdalena Kościelna, Małgorzata Kinda, Andriy Yarka, Luke Stewart, Wojciech Witkiewicz. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter 2017; 22(2) doi: 10.1111/hel.12365
|
| 35 |
Jiunn-Wei Wang, Chien-Ning Hsu, Wei-Chen Tai, Ming-Kun Ku, Tsung-Hsing Hung, Kuo-Lun Tseng, Lan-Ting Yuan, Seng-Howe Nguang, Chih-Ming Liang, Shih-Cheng Yang, Cheng-Kun Wu, Pin-I Hsu, Deng-Chyang Wu, Seng-Kee Chuah, Giuseppe Remuzzi. The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer Diseases. PLOS ONE 2016; 11(10): e0164824 doi: 10.1371/journal.pone.0164824
|
| 36 |
F. Sierra, J.D. Forero, M. Rey. Tratamiento ideal del Helicobacter pylori: una revisión sistemática. Revista de Gastroenterología de México 2014; 79(1): 28 doi: 10.1016/j.rgmx.2013.03.003
|
| 37 |
Pramodini B. Kale‐Pradhan, Anela Mihaescu, Sheila M. Wilhelm. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2015; 35(8): 719 doi: 10.1002/phar.1614
|
| 38 |
Mireia Baylina, Neus Muñoz, Jordi Sánchez‐Delgado, Sheila López‐Góngora, Xavier Calvet, Ignasi Puig. Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced?. Helicobacter 2019; 24(3) doi: 10.1111/hel.12584
|
| 39 |
Neus Muñoz, Jordi Sánchez‐Delgado, Mireia Baylina, Ignasi Puig, Sheila López‐Góngora, David Suarez, Xavier Calvet. Systematic review, meta‐analysis, and meta‐regression: Successful second‐line treatment for Helicobacter pylori. Helicobacter 2018; 23(3) doi: 10.1111/hel.12488
|
| 40 |
Yuri Kim, Ji Yong Ahn, Hwoon-Yong Jung, Jin Hee Noh, Hee Kyong Na, Kee Wook Jung, Jeong Hoon Lee, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee. Comparison of Helicobacter pylori Eradication Rates Using Standard Triple Therapy and Sequential Therapy. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(4): 277 doi: 10.7704/kjhugr.2023.0042
|
| 41 |
Antonio Rollan, Juan Pablo Arab, M Constanza Camargo, Roberto Candia, Paul Harris, Catterina Ferreccio, Charles S Rabkin, Juan Cristóbal Gana, Pablo Cortés, Rolando Herrero, Luisa Durán, Apolinaria García, Claudio Toledo, Alberto Espino, Nicole Lustig, Alberto Sarfatis, Catalina Figueroa, Javier Torres, Arnoldo Riquelme. Management of <italic>Helicobacter pylori</italic> infection in Latin America: A Delphi technique-based consensus. World Journal of Gastroenterology 2014; 20(31): 10969-10983 doi: 10.3748/wjg.v20.i31.10969
|
| 42 |
Joshua P. Owings, Nina N. McNair, Yiu Fung Mui, Tomas N. Gustafsson, Arne Holmgren, Maria Contel, Joanna B. Goldberg, Jan R. Mead, Lígia Saraiva. Auranofin andN-heterocyclic carbene gold-analogs are potent inhibitors of the bacteriaHelicobacter pylori. FEMS Microbiology Letters 2016; 363(14): fnw148 doi: 10.1093/femsle/fnw148
|
| 43 |
Gaël Tchokomeni Siwe, Rukesh Maharjan, André Perfusion Amang, Christophe Mezui, Nkwengoua Ernestine Zondegoumba, George Enonchong Enow-Orock, Muhammad Iqbal Choudhary, Paul Vernyuy Tan. Eremomastax speciosa (Hochst.) Cufod. counteracts the delaying effect of indomethacin on Helicobacter pylori-associated chronic gastric ulcers healing. Journal of Ethnopharmacology 2021; 279: 114374 doi: 10.1016/j.jep.2021.114374
|
| 44 |
Amin Talebi Bezmin Abadi. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017; 8: 123 doi: 10.1016/j.jgar.2016.11.008
|
| 45 |
Ping-I Hsu, Pei-Chin Lin, David Y Graham. Hybrid therapy for <italic>Helicobacter pylori</italic> infection: A systemic review and meta-analysis. World Journal of Gastroenterology 2015; 21(45): 12954-12962 doi: 10.3748/wjg.v21.i45.12954
|
| 46 |
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi. The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure inHelicobacter pyloriEradication. The Korean Journal of Gastroenterology 2017; 70(2): 72 doi: 10.4166/kjg.2017.70.2.72
|
| 47 |
I. Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. Valasek. Review article: the global emergence ofHelicobacter pyloriantibiotic resistance. Alimentary Pharmacology & Therapeutics 2016; 43(4): 514 doi: 10.1111/apt.13497
|
| 48 |
Chih-Ming Liang, Chien-Hua Chiu, Hsing-Ming Wang, Wei-Chen Tai, Chih-Chien Yao, Cheng-En Tsai, Chung-Mou Kuo, Yi-Chun Chiu, Keng-Liang Wu, Chen-Hsiang Lee, Kai-Lung Tsai, Chih-Fang Huang, Seng-Kee Chuah. First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan. BioMed Research International 2017; 2017: 1 doi: 10.1155/2017/3762194
|
| 49 |
F. Sierra, J. D. Forero, M. Rey, M. L. Botero, A. Cárdenas. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2013; 37(12): 1165 doi: 10.1111/apt.12329
|
| 50 |
Jihee Sung, Nayoung Kim, Yo Han Park, Young Jae Hwang, Soohoon Kwon, Gyeongjae Na, Joon Young Choi, Jae Bin Kang, Hye Rang Kim, Jin-Wook Kim, Dong Ho Lee. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with forHelicobacter pyloriEradication Failure. The Korean Journal of Gastroenterology 2017; 69(2): 109 doi: 10.4166/kjg.2017.69.2.109
|
| 51 |
|
| 52 |
Hafez Fakheri, Zohreh Bari, Hossein Sardarian. A modified Bismuth‐Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy Failure. Helicobacter 2012; 17(4): 264 doi: 10.1111/j.1523-5378.2012.00946.x
|
| 53 |
Sung Woo Jung, Sang Woo Lee. The antibacterial effect of fatty acids on <i>Helicobacter pylori</i> infection. The Korean Journal of Internal Medicine 2015; 31(1): 30 doi: 10.3904/kjim.2016.31.1.30
|
| 54 |
S Kane-Dumbre, M. Momin, P. Ravikumar, R. Khatri. DRUG DELIVERY STRATEGIES FOR HELICOBACTER PYLORI INFECTION MANAGEMENT: AN OVERVIEW. INDIAN DRUGS 2019; 56(10): 7 doi: 10.53879/id.56.10.11811
|
| 55 |
Seng‐Kee Chuah, Ping‐I Hsu, Kuo‐Chin Chang, Yi‐Chun Chiu, Keng‐Liang Wu, Yeh‐Pin Chou, Ming‐Luen Hu, Wei‐Chen Tai, King‐Wah Chiu, Shue‐Shian Chiou, Deng‐Chyang Wu, Tsung‐Hui Hu. Randomized Comparison of Two Non‐Bismuth‐Containing Second‐line Rescue Therapies for Helicobacter pylori. Helicobacter 2012; 17(3): 216 doi: 10.1111/j.1523-5378.2012.00937.x
|
| 56 |
Mounia Lahbabi, Samia Alaoui, Karima El Rhazi, Mohammed El Abkari, Chakib Nejjari, Afaf Amarti, Bahia Bennani, Mustapha Mahmoud, Adil Ibrahimi, Dafr Allah Benajah. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study. Clinics and Research in Hepatology and Gastroenterology 2013; 37(4): 416 doi: 10.1016/j.clinre.2012.10.002
|
| 57 |
Chao-Hung Kuo, Fu-Chen Kuo, Huang-Ming Hu, Chung-Jung Liu, Sophie S. W. Wang, Yen-Hsu Chen, Ming-Chia Hsieh, Ming-Feng Hou, Deng-Chyang Wu. The Optimal First-Line Therapy ofHelicobacter pyloriInfection in Year 2012. Gastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/168361
|
| 58 |
Jing Yu, Hui Ye, Jiang Li, Ning Li, Zong-ming Shi, Xue-zhi Zhang. The Antibacterial Activity of Mass Galla Chinesis et Camelliae Fermentata on Helicobacter pylori Infection. Evidence-Based Complementary and Alternative Medicine 2018; 2018: 1 doi: 10.1155/2018/1491732
|
| 59 |
Eva M. Kulik Kunz, Krystyna Lenkeit, Tuomas Waltimo, Roland Weiger, Clemens Walter. Combinatorial effects of amoxicillin and metronidazole on selected periodontal bacteria and whole plaque samples. Archives of Oral Biology 2014; 59(6): 608 doi: 10.1016/j.archoralbio.2014.03.007
|
| 60 |
Cheng‐En Tsai, Chih‐Ming Liang, Chen‐Hsiang Lee, Yuan‐Hung Kuo, Keng‐Liang Wu, Yi‐Chun Chiu, Wei‐Chen Tai, Seng‐Kee Chuah. First‐line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. The Kaohsiung Journal of Medical Sciences 2016; 32(8): 397 doi: 10.1016/j.kjms.2016.05.012
|
| 61 |
Cuimeng Tian, Keqiang Chen, Wanghua Gong, Teizo Yoshimura, Jiaqiang Huang, Ji Ming Wang. The G-Protein Coupled Formyl Peptide Receptors and Their Role in the Progression of Digestive Tract Cancer. Technology in Cancer Research & Treatment 2020; 19: 153303382097328 doi: 10.1177/1533033820973280
|
| 62 |
Yifan Lin, Yongfu Shao, Jianing Yan, Guoliang Ye. Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice. Journal of Clinical Laboratory Analysis 2023; 37(7) doi: 10.1002/jcla.24885
|
| 63 |
Ekaterina Gavrish, Binu Shrestha, Chao Chen, Ida Lister, E. Jeffrey North, Lei Yang, Richard E. Lee, Angel Han, Bronwyn Williams, David Charnuska, Ken Coleman, Kim Lewis, Michael D. LaFleur.
In Vitro
and
In Vivo
Activities of HPi1, a Selective Antimicrobial against Helicobacter pylori
. Antimicrobial Agents and Chemotherapy 2014; 58(6): 3255 doi: 10.1128/AAC.02573-13
|
| 64 |
Peng Bai, Li Ya Zhou, Xiu Mei Xiao, Yang Luo, Yu Ding. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. Journal of Digestive Diseases 2015; 16(8): 464 doi: 10.1111/1751-2980.12271
|
| 65 |
A. O. Pozdeeva, O. K. Pozdeev, P. E. Gulyaev, Yu. V. Valeeva, A. N. Savinova. Current development of <i>Helicobacter pylori</i> eradication protocols. Russian Journal of Infection and Immunity 2021; 11(6): 1037 doi: 10.15789/2220-7619-CDO-1679
|
| 66 |
Hyung Min Noh, Su Jin Hong, Jae Pil Han, Kyung Woo Park, Yun Nah Lee, Tae Hee Lee, Bong Min Ko, Joon Seong Lee, Moon Sung Lee. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin afterHelicobacter pyloriTreatment Failure in Clinical Practice. The Korean Journal of Gastroenterology 2016; 68(5): 260 doi: 10.4166/kjg.2016.68.5.260
|
| 67 |
Soohoon Kwon, Dong Ho Lee, Jae Bin Kang, Nayoung Kim, Young Soo Park, Cheol Min Shin, Hyuk Yoon, Yoon Jin Choi. The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure inHelicobacter pyloriEradication. The Korean Journal of Gastroenterology 2018; 71(4): 196 doi: 10.4166/kjg.2018.71.4.196
|
| 68 |
Sukhbir K Shahid. Novel anti-Helicobacter pylori therapies. Pharmaceutical Patent Analyst 2014; 3(4): 411 doi: 10.4155/ppa.14.27
|
| 69 |
Jun‐Won Chung, Young Kul Jung, Yoon Jae Kim, Kwang Ahn Kwon, Jung Ho Kim, Jong Joon Lee, Sung Min Lee, Ki Baik Hahm, Sun Mi Lee, Jin Yong Jeong, Sung‐Cheol Yun. Ten‐day sequential versus triple therapy for Helicobacter pylori eradication: A prospective, open‐label, randomized trial. Journal of Gastroenterology and Hepatology 2012; 27(11): 1675 doi: 10.1111/j.1440-1746.2012.07249.x
|
| 70 |
Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. Advances in Therapy 2017; 34(5): 1070 doi: 10.1007/s12325-017-0532-9
|
| 71 |
Acacia Lamb, Lin‐Feng Chen. Role of the Helicobacter pylori‐Induced inflammatory response in the development of gastric cancer. Journal of Cellular Biochemistry 2013; 114(3): 491 doi: 10.1002/jcb.24389
|
| 72 |
Yingling Jiang, Lifang Huang, Lihua Zhou. Association between obesity and helicobacter pylori infection. Nutrition Clinique et Métabolisme 2022; 36(3): 210 doi: 10.1016/j.nupar.2022.07.003
|
| 73 |
Feng‐Woei Tsay, Deng‐Chyang Wu, Sung‐Shuo Kao, Tzung‐Jium Tsai, Kwok‐Hung Lai, Jin‐Shiung Cheng, Hoi‐Hung Chan, Huay‐Min Wang, Wei‐Lun Tsai, Hui‐Hwa Tseng, Nan‐Jin Peng, Ping‐I Hsu. Reverse Sequential Therapy Achieves a Similar Eradication Rate as Standard Sequential Therapy for Helicobacter pylori Eradication: A Randomized Controlled Trial. Helicobacter 2015; 20(1): 71 doi: 10.1111/hel.12176
|
| 74 |
Katayoun Borhani, Ashraf Mohabati Mobarez, Ali Reza Khabiri, Mehrdad Behmanesh, Nima Khoramabadi. Inhibitory effects of rHP-NAP IgY against Helicobacter pylori attachment to AGS cell line. Microbial Pathogenesis 2016; 97: 231 doi: 10.1016/j.micpath.2016.06.004
|
| 75 |
Maria Harmati, Edina Gyukity‐Sebestyen, Gabriella Dobra, Gabriella Terhes, Edit Urban, Gabor Decsi, Neda Mimica‐Dukić, Marija Lesjak, Nataša Simin, Bernadett Pap, Istvan B. Nemeth, Krisztina Buzas. Binary mixture of Satureja hortensis and Origanum vulgare subsp. hirtum essential oils: in vivo therapeutic efficiency against Helicobacter pylori infection. Helicobacter 2017; 22(2) doi: 10.1111/hel.12350
|
| 76 |
Jayaram Lakshmaiah Narayana, Han-Ning Huang, Chang-Jer Wu, Jyh-Yih Chen. Epinecidin-1 antimicrobial activity: In vitro membrane lysis and In vivo efficacy against Helicobacter pylori infection in a mouse model. Biomaterials 2015; 61: 41 doi: 10.1016/j.biomaterials.2015.05.014
|
| 77 |
Seng-Kee Chuah, Deng-Chyang Wu, Hidekazu Suzuki, Khean-Lee Goh, John Kao, Jian-Lin Ren. Peptic Ulcer Diseases: Genetics, Mechanism, and Therapies. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/898349
|
| 78 |
P. Nazari, R. Dowlatabadi-Bazaz, M. R. Mofid, M. R. Pourmand, N. E. Daryani, M. A. Faramarzi, Z. Sepehrizadeh, A. R. Shahverdi. The Antimicrobial Effects and Metabolomic Footprinting of Carboxyl-Capped Bismuth Nanoparticles Against Helicobacter pylori. Applied Biochemistry and Biotechnology 2014; 172(2): 570 doi: 10.1007/s12010-013-0571-x
|
| 79 |
Te-Fu Lin, Ping-I Hsu. Second-line rescue treatment of <i>Helicobacter pylori</i> infection: Where are we now?. World Journal of Gastroenterology 2018; 24(40): 4548-4553 doi: 10.3748/wjg.v24.i40.4548
|
| 80 |
Nuno Almeida, Maria Manuel Donato, José Manuel Romãozinho, Cristina Luxo, Olga Cardoso, Maria Augusta Cipriano, Carol Marinho, Alexandra Fernandes, Carlos Sofia. Correlation of Helicobacter pylori Genotypes with Gastric Histopathology in the Central Region of a South-European Country. Digestive Diseases and Sciences 2015; 60(1): 74 doi: 10.1007/s10620-014-3319-8
|
| 81 |
Shen-Shong Chang, Hsiao-Yun Hu. <italic>Helicobacter pylori</italic>: Effect of coexisting diseases and update on treatment regimens. World Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 127-136 doi: 10.4292/wjgpt.v6.i4.127
|
| 82 |
Lucinda J. Bessa, Rossella Grande, Donato DI Iorio, Mara DI Giulio, Emanuela DI Campli, Luigina Cellini. Helicobacter pylori free‐living and biofilm modes of growth: behavior in response to different culture media. APMIS 2013; 121(6): 549 doi: 10.1111/apm.12020
|
| 83 |
Bekir Kocazeybek, Hrisi Bahar Tokman. Prevalence of Primary Antimicrobial Resistance of H. pylori in Turkey: A Systematic Review. Helicobacter 2016; 21(4): 251 doi: 10.1111/hel.12272
|
| 84 |
Hang Yeon Jeong, Tae Ho Lee, Ju Gyeong Kim, Sueun Lee, Changjong Moon, Xuan Trong Truong, Tae-Il Jeon, Jae-Hak Moon. 3-Pentylcatechol, a Non-Allergenic Urushiol Derivative, Displays Anti-Helicobacter pylori Activity In Vivo. Pharmaceuticals 2020; 13(11): 384 doi: 10.3390/ph13110384
|
| 85 |
Nuno Almeida, José M. Romãozinho, Maria M. Donato, Cristina Luxo, Olga Cardoso, Maria A. Cipriano, Carol Marinho, Carlos Sofia. Triple Therapy with High‐Dose Proton‐Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless for Helicobacter pylori Eradication: A Proof‐of‐Concept Study. Helicobacter 2014; 19(2): 90 doi: 10.1111/hel.12106
|
| 86 |
Ping-I Hsu, Nan-Jing Peng. H. pyloriEradication Therapy. Gastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/935635
|
| 87 |
Xue-Yuan Cao, Zhi-Fang Jia, Dong-Hui Cao, Fei Kong, Mei-Shan Jin, Jian Suo, Jing Jiang. DNMT3a rs1550117 Polymorphism Association with Increased Risk of Helicobacter pylori Infection. Asian Pacific Journal of Cancer Prevention 2013; 14(10): 5713 doi: 10.7314/APJCP.2013.14.10.5713
|
| 88 |
M. Gasparetto, M. Pescarin, G. Guariso. Helicobacter pyloriEradication Therapy: Current Availabilities. ISRN Gastroenterology 2012; 2012: 1 doi: 10.5402/2012/186734
|
| 89 |
Angelo Zullo, Cesare Hassan, Lorenzo Ridola, Vincenzo De Francesco, Dino Vaira. Standard triple and sequential therapies for Helicobacter pylori eradication: An update. European Journal of Internal Medicine 2013; 24(1): 16 doi: 10.1016/j.ejim.2012.07.006
|
| 90 |
Jun-Won Chung, Minsu Ha, Sung-Cheol Yun, Jung Ho Kim, Jong Jun Lee, Yoon Jae Kim, Kyoung Oh Kim, Kwang An Kwon, Dong Kyun Park, Dong Ho Lee. Meta-analysis: Sequential Therapy Is Superior to Conventional Therapy forHelicobacter pyloriInfection in Korea. The Korean Journal of Gastroenterology 2013; 62(5): 267 doi: 10.4166/kjg.2013.62.5.267
|
| 91 |
Hyasinta Jaka, Andreas Mueller, Christa Kasang, Stephen E. Mshana. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infectious Diseases 2019; 19(1) doi: 10.1186/s12879-019-4085-1
|
| 92 |
Olga Cardoso, Maria Manuel Donato, Cristina Luxo, Nuno Almeida, Joana Liberal, Artur Figueirinha, Maria Teresa Batista. Anti- Helicobacter pylori potential of Agrimonia eupatoria L. and Fragaria vesca. Journal of Functional Foods 2018; 44: 299 doi: 10.1016/j.jff.2018.03.027
|
| 93 |
Morris O. Makobongo, Leo Einck, Richard M. Peek, D. Scott Merrell, Asad U Khan. In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against Helicobacter pylori. PLoS ONE 2013; 8(7): e68917 doi: 10.1371/journal.pone.0068917
|
| 94 |
Amin Talebi Bezmin Abadi. Therapy ofHelicobacter pylori: Present Medley and Future Prospective. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/124607
|
| 95 |
Wei-Chen Tai, Chen-Hsiang Lee, Shue-Shian Chiou, Chung-Mou Kuo, Chung-Huang Kuo, Chih-Ming Liang, Lung-Sheng Lu, Chien-Hua Chiu, Keng-Liang Wu, Yi-Chun Chiu, Tsung-Hui Hu, Seng-Kee Chuah, Ivo G. Boneca. The Clinical and Bacteriological Factors for Optimal Levofloxacin-Containing Triple Therapy in Second-Line Helicobacter pylori Eradication. PLoS ONE 2014; 9(8): e105822 doi: 10.1371/journal.pone.0105822
|
| 96 |
Halil Rakici, Teslime Ayaz, Remzi Adnan Akdogan, Recep Bedir. Comparison of Levofloxacin- and Moxifloxacin-Based Triple Therapies with Standard Treatment in Eradication of Helicobacter Pylori as First-Line Therapy. Digestion 2014; 90(4): 261 doi: 10.1159/000369788
|
| 97 |
Seng-Kee Chuah, Chih-Ming Liang, Chen-Hsiang Lee, Shue-Shian Chiou, Yi-Chun Chiu, Ming-Luen Hu, Keng-Liang Wu, Lung-Sheng Lu, Yeh-Pin Chou, Kuo-Chin Chang, Chung-Huang Kuo, Chung-Mou Kuo, Tsung-Hui Hu, Wei-Chen Tai. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication. Medicine 2016; 95(19): e3586 doi: 10.1097/MD.0000000000003586
|
| 98 |
Ping-I Hsu, Sung-Shuo Kao, Deng-Chyang Wu, Wen-Chi Chen, Nan-Jing Peng, Hsien-Chung Yu, Huay-Min Wang, Kwok-Hung Lai, Jin-Shiung Cheng, Angela Chen, Seng-Kee Chuah, Feng-Woei Tsay. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. Medicine 2015; 94(48): e2104 doi: 10.1097/MD.0000000000002104
|
| 99 |
Thomas A Keating. Resistance mechanism to an uncompetitive inhibitor of a single-substrate, single-product enzyme: a study of Helicobacter pylori glutamate racemase. Future Medicinal Chemistry 2013; 5(11): 1203 doi: 10.4155/fmc.13.94
|
| 100 |
Sotirios D. Georgopoulos, Vasilios Papastergiou, Stylianos Karatapanis. Helicobacter pyloriEradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/757926
|
| 101 |
Faezeh Kiani, Sara Khademolhosseini, Mobina Fathi, Arian Tavasol, Jasem Mohammadi, Majid Dousti, Jalal Eshagh Hoseini. Standard Triple Therapy as a Remedy for Treatment of Helicobacter pylori
Infection: A Systematic Review and Meta-analysis of Randomized Clinical
Trials. Current Reviews in Clinical and Experimental Pharmacology 2023; 18(2): 167 doi: 10.2174/2772432817666220317152544
|
| 102 |
Maliheh Safavi, Mohammadreza Shams-Ardakani, Alireza Foroumadi. Medicinal plants in the treatment ofHelicobacter pyloriinfections. Pharmaceutical Biology 2015; 53(7): 939 doi: 10.3109/13880209.2014.952837
|
| 103 |
Nuno Almeida, Maria Manuel Donato, José Manuel Romãozinho, Cristina Luxo, Olga Cardoso, Maria Augusta Cipriano, Carol Marinho, Alexandra Fernandes, Carlos Calhau, Carlos Sofia. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?. BMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0245-y
|
| 104 |
Yi-Chun Chiu, Wei-Chen Tai, Seng-Kee Chuah, Ping-I Hsu, Deng-Chyang Wu, Keng-Liang Wu, Chao-Cheng Huang, Ji-Chen Ho, Johannes Ring, Wen-Chieh Chen. The Clinical Correlations ofHelicobacter pyloriVirulence Factors and Chronic Spontaneous Urticaria. Gastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/436727
|